TAVR stands for Transcatheter Aortic Valve Replacement. The heart has four valves that makes sure the blood goes in the right ...
The following is a summary of "Transcatheter Aortic Valve Replacement Beyond Severe Aortic Stenosis: JACC State-of-the-Art ...
Medical Device Network on MSN17h
Medtronic announces two-year trial outcomes of Evolut TAVRMedtronic has announced the Small Annuli Randomized To Evolut or SAPIEN (SMART) head-to-head comparative trial’s two-year ...
Early surgical or transcatheter aortic valve replacement is not typically recommended for severe aortic stenosis in the ...
The following is a summary of "Transcatheter vs Surgical Aortic Valve Replacement in Lower-Risk Patients: An Updated ...
Capstan CEO Maggie Nixon discusses first-in-human feedback, the all-at-once approach, regulatory strategy and the tricuspid ...
Medtronic (MDT) released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN, SMART, Trial, the largest international ...
"Today marks a pivotal moment in the evolution of structural heart therapy," Capstan Medical CEO Maggie Nixon said.
The money will support an ongoing pivotal trial of 4C Medical Technologies' transcatheter mitral valve replacement device in ...
Pi-Cardia today announced the first commercial procedures with its ShortCut leaflet modification device for enabling heart ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today released the two-year results of the SMall Annuli Randomized To Evolut or SAPIEN (SMART) Trial, the largest international ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback